9306-051 
930 ^ 4^53 
9300-053 
9309-054 
9309-055 
9309-056 
9309-057 
9309-058 
9313-059 
9313-060 
9313-061 
9313-063 
9313-063 
93 12-064 
9312-065 
I 
I 
Attachment II - Page 5 ! 
i 
I 
I 
f 
(T) Hcsdorffer, Charles and Antman, Karen, Columbia University College of Physicians and Surgeons, New York, New York; Human 
MDR Gene Transfer in Patients with Advanced Cancer. 
RAC Approval: 6-8-93/NIH Approval: 9-3-93 i 
I! 
(T) Dan, Joseph, Case Western Reserve University School of Medicine and University Hospitals of Qeveland, Qeveland, Ohio; Gene ' 
Therapy for Human Brain Tumors Using Episome-Based Antisense cDNA Transcription of Insutin-Uke Growth Factor /. 
RAC Approval: 6-8-93/NIH Ajjproval: 12-2-93 | 
(T) Cassileth, Peter, Podack, Eckhard R.; Sridhar, Kasi; University of Miami, and Savaraj, Niramol; Miami Veterans Administration 
Hospital, Miami, Florida; Phase I Study of Transfected Cancer Cells Expressing the lnterieukin-2 Gene Product in Limited Stage Small 
Cell Lung Cancer. 
RAC Approval: 9-9-93/NIH Approval: 12-2-93 s 
I 
(T) O’Shaughnessy, Joyce; National Institutes of Health, Bethesda, Maryland; Retroviral Mediated Transfer of the Human Multi-Drug ’ 
Resistance Gene (MDR-1) into Hematopoietic Stem Cells During Autologous Transplantation after Intensive Chemotherapy for Breast | 
Cancer. f 
RAC Approval: 9-9-93/NIH Approval: 10-7-93 i 
(T) Kun, Larry E.; Sanford, R. A; Brenner, Malcolm K.; and Heideman, Richard L.; St Jude Childrens Research Hospital, Memphis, 
Tennessee; and Oldfield, Edward H.; National Institutes of Health, Bethesda, Maryland; Gene Therapy for Recurrent Pediatric Brain t 
Tumors. 
RAC Approval: 9-9-93/NIH Approval: 10-7-93 
(T) Das Gupta. Tanas K. and Cohen. Edward P.: Unrversitv of Illinois at Chicago: Chicago. Illinois: Immunization of Malignant • 
Melanoma Patients with InterieuJan 2-Secreting Melanoma Cells Expressing Defined Allogeneic Histocompatibility Antigens. ^ 
RAC Approval: 9-10-93 « 
I 
(T) Wong-Staal. Flossie: Poeschla. Eric; and Looney. David: Unrversitv of California. San Diego. California; A Phase I Clinical Trial to | 
Evaluate the Safety and Effects in HTV-l Infected Humans of Autologous Lymphocytes Transduced with a Ribozvme that Cleaves HIV-1 j 
RNA. 
RAC Approval: 9-10-93 ‘ 
(T) Economou, James S. and Glasby, John A; University of California Medical Center, Los Angeles, California; Genetically Engineered I 
Autologous Tumor Vaccines Producing Interieukin-2 for the Treatment of Metastatic Melanoma. 
RAC Approval: 9-10-93/NIH Approval: 12-2-93 
I 
(T) Oldfield, Edward H. and Ram, Zvi; NIH, Bethesda, Maryland; Intrathecal Gene Therapy for the Treatment of Leptomeningeal i 
Carcinomatosis. 
RAC Approval: 12-2-93/NIH Approval: 1/20/94 1 
(T) Sobol. Robert E and Rovston. Ivon San Diego Regional Cancer Center. San Diego. California: Injection of Colon Carcinoma ^ 
Patients with Autologous Irradiated Tumor Cells and Fibroblasts GeneticaUv Modified to Secrete Interieukin-2. 
RAC Approval: 12-2-93 
(T) Schuening. Friedrich: Fred Hutchinson Cancer Research Center. Seattle. Washington: Retrovirus-Mediated Transfer of the cDNA for \ 
Human Giucocerebrosidase into Peripheral Blood Reoopulatine Cells of Patients with Gaucher's Disease. \ 
RAC Approval: 12-2-93 
(T) Haubrich. Richard: Unrversitv of California at San Diego Treatment Center. San Diego. California; An Open Label. Phase I/H i 
Clinical Trial to Evaluate the Safety and Biological Activity of HTV-mV) fHTV-l DBenv/Retroviral Vector) in HTV-l Infected Subjects. 
RAC Approval: 12-3-93 
(T) Sznol. Mario: NIH. Frederick. Maryland: A Phase I Trial of B7-Transfected Lethallv Irradiated Allogeneic Melanoma Cell Lines to 
Induce Cell Mediated Immunity Against Tumor-Associated Antigens Presented bv HLA-A2 or HIA-AI in Patients with Stage IV 
Melanoma. 
RAC Approval: 12-3-93 ^ 
(T) Rubin. Joseph. Mayo Qinic. Rochester. Minnesota: Phase I Study of Immunotherapy of Advance Colorectal Carcinoma by Direct Gene \ 
Transfer into Hepatic Metastases. 
RAC Approval: 12-3-93 
(T) Chang. Alfred E.. University of Michigan. Ann Arbor. Michigan: Adoptive Immunotherairv of Melanoma with Activated Lymph Node 
Cells Primed In Vivo with Autologous Tumor Cells Transduced with the IL-4 Gene. 
RAC Approval: 12-3-93 
[ 76 ] 
Recombinant DNA Research, Volume 19 
